Insider Selling: Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Sells 62,200 Shares of Stock

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) major shareholder Global Strategic Fund I. Venbio sold 62,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $10.38, for a total transaction of $645,636.00. Following the sale, the insider now directly owns 3,125,640 shares of the company’s stock, valued at approximately $32,444,143.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of CMPI stock opened at $10.39 on Friday. Checkmate Pharmaceuticals, Inc. has a 1 year low of $2.00 and a 1 year high of $10.45. The firm has a fifty day moving average price of $3.67 and a 200-day moving average price of $3.44. The company has a market cap of $224.75 million, a price-to-earnings ratio of -3.66 and a beta of 0.61.

Checkmate Pharmaceuticals (NASDAQ:CMPIGet Rating) last issued its quarterly earnings data on Tuesday, March 29th. The company reported ($0.62) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Checkmate Pharmaceuticals, Inc. will post -3.14 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Checkmate Pharmaceuticals stock. Millennium Management LLC bought a new stake in shares of Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,633 shares of the company’s stock, valued at approximately $31,000. Institutional investors own 75.12% of the company’s stock.

A number of research firms have commented on CMPI. BTIG Research downgraded shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday. Zacks Investment Research raised shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday.

Checkmate Pharmaceuticals Company Profile (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

Featured Stories

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with's FREE daily email newsletter.